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FPCLDupuytren's disease (DD) is a common ﬁbrotic condition of the palmar fascia, leading to deposition of collagen-
rich cords and progressive ﬂexion of the ﬁngers. The molecular mechanisms underlying the disease are poorly
understood. We have previously shown altered expression of extracellular matrix-degrading proteases (matrix
metalloproteases,MMPs, and ‘a disintegrin andmetalloprotease domainwith thrombospondinmotifs’, ADAMTS,
proteases) in palmar fascia from DD patients compared to control and shown that the expression of a sub-set of
these genes correlates with post-operative outcome. In the current study we used an in vitromodel of collagen
contraction to identify the speciﬁc proteases which mediate this effect. We measured the expression of all
MMPs, ADAMTSs and their inhibitors in ﬁbroblasts derived from the palmar fascia of DD patients, both in mono-
layer culture and in the ﬁbroblast-populated collagen lattice (FPCL) model of cell-mediated contraction. Key
proteases, previously identiﬁed in our tissue studies, were expressed in vitro and regulated by tension in the
FPCL, including MMP1, 2, 3, 13 and 14. Knockdown of MMP2 and MMP14 (but not MMP1, 3 and 13) inhibited
cell-mediated contraction, and knockdown ofMMP14 inhibited proMMP-2 activation. Interestingly, whilst colla-
gen is degraded during the FPCL assay, this is not altered upon knockdown of any of the proteases examined.We
conclude that MMP-14 (via its ability to activate proMMP-2) and MMP-2 are key proteases in collagen contrac-
tionmediated by ﬁbroblasts in DD patients. These proteasesmay be drug targets or act as biomarkers for disease
progression.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Dupuytren's disease (DD) is a common condition causing ﬁxed ﬂex-
ion deformity of the digits with reported prevalence between 0.2% and
56% depending on age, population and methodology of the study [1].
Clinically, it is characterised by ﬁbrosis of the palmar fascia with
contraction of the digits potentially mediated by the formation and
proliferation of myoﬁbroblasts. Three distinct histological phases have
been described [2] with: a proliferative phase leading to the develop-
ment of a nodular lesion, an involutional phase where cells align them-
selves to lines of stresswith concomitant contraction of the tissue, and a
residual phase leaving a scar-like cord tissue. Risk factors include age,
sex, alcohol and tobacco intake, trauma, diabetes, epilepsy and
hyperlipidaemia [3]. The disease is often familial but the mode ofroteinase domain with throm-
last-populated collagen lattice;
+44 1603 592250.
rights reserved.inheritance is currently unknown [4]. A recent genomewide association
study highlighted loci relevant to the Wnt signaling pathway as
involved in the genetic susceptibility to Dupuytren's disease [5].
Mechanical disruption of the ﬁbrotic material through surgical in-
tervention to allow ﬁnger extension remains the most common treat-
ment. Techniques range from minimally invasive needle fasciotomy,
excision of the ﬁbrous cords (fasciectomy) or most aggressively,
excision of skin and DD material with full thickness skin grafts
(dermofasciectomy). None of these operations, which can be associ-
ated with signiﬁcant complications, fundamentally affect underlying
disease activity and this is conﬁrmed by high recurrence rates [3].
Enzymatic fasciotomy using clostridium-derived collagenases has
recently been approved as a non-surgical alternative [6] but mirrors
needle fasciotomy with only partial improvement and high recur-
rence rates of proximal interphalangeal joint contractures. Disease
progression and post-surgical prognosis is difﬁcult to predict and
there are no useful biomarkers.
The matrix metalloproteases (MMPs) are a family of 23 enzymes
in man, which include the only mammalian enzymes able to degrade
the collagen triple helix in a speciﬁc manner under physiological
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the human enzymes. More recently, MMP-2 (gelatinase A) and
MMP-14 (MT1-MMP) have also been shown to make this speciﬁc
cleavage though with less catalytic efﬁciency [8–10]. Other MMPs
are also implicated in collagen turnover, e.g. MMP-3, by virtue of
its ability to activate the pro-enzyme form of MMP-1 [11]. A related
family of metalloproteases, the ADAMTSs (a disintegrin and metallo-
protease domain with thrombospondin motif), number 19 enzymes
in man and are also implicated in extracellular matrix (ECM) metab-
olism. These include enzymes capable of degrading the proteoglycan,
aggrecan (at least ADAMTS-1, -4, -5, -8, -9 and -15), and three procol-
lagen N-propeptidases (ADAMTS-2, -3 and -14). Many other mem-
bers of this family are of unknown function [12]. A family of four
speciﬁc inhibitors, the TIMPs, have been described [13]. Whilst the
ability of the four TIMPs to inhibit MMPs is largely promiscuous, a
number of functional differences have been noted, e.g. TIMP-2, -3
and -4, but not TIMP-1, are effective inhibitors of the membrane-
type metalloprotease (MT-MMP) subclass. Speciﬁcity amongst the
TIMPs for inhibition of the ADAMTS family of metalloproteases has
also been described with TIMP-3 being a potent inhibitor of e.g.
ADAMTS-4 (aggrecanase-1) and ADAMTS-5 (aggrecanase-2) [14]. In
many ﬁbrotic diseases such as those affecting liver, lung, and skin,
MMPs (and related metalloproteases) and TIMPs play an important
role. Normal ECM turnover can be viewed as a balance between prote-
ase and inhibitor activities (presuming synthesis remains unaltered),
with ﬁbrosis coming from an imbalance away from proteolysis [7].
In the 1980s and 1990s, several small molecule inhibitors of MMPs
underwent clinical trials in a variety of cancers [15]. The major side-
effect of these drugs was a so-called ‘musculoskeletal syndrome’,
often referred to as musculoskeletal pain accompanied by tendonitis
[16,17]. This was dose- and time-dependent and reversible on stopping
treatment, but did not respondwell toNSAIDs or low dose steroid treat-
ment. The clinical presentation,where reported in detail, is described as
frozen shoulder or a condition resembling Dupuytren's disease [18].
Both of these conditions involve similar ﬁbrotic mechanisms (of the
shoulder joint capsule in the case of frozen shoulder), the laying
down of a collagen-rich ECM and the involvement of myoﬁbroblast-
mediated contraction [19,20]. Whilst Dupuytren's disease and frozen
shoulder have very different natural histories (the former a progressive
disease, the latter usually self-limiting and resolving in time), they may
well share common pathways leading to contracture [19]. The MMP
inhibitors that cause the ‘musculoskeletal syndrome’ are ‘pan-MMP’
inhibitors, showing an approximately nanomolar (or lower) inhibition
constant against many of the MMPs tested. Moreover, there is good
evidence that they may also inhibit related metalloproteases e.g.
ADAMTSs. Indeed, the musculoskeletal syndrome is usually ascribed
to the inhibition of non-target metalloproteases.
Previously, measurement of small sub-sets of MMPs and TIMPs
had been undertaken in DD tissues or in patient sera, but none of
these was comprehensive [21–24]. We recently assayed the expres-
sion of the entire MMP, TIMP and ADAMTS gene families in DD tissue
(nodule and cord) compared to normal palmar fascia using qRT-PCR
[25]. The expression of a number of enzymes was raised in DD nodule
including four collagenolytic proteases, MMP1, MMP2, MMP13 and
MMP14, as well as TIMP1. We also followed DD patients for 2 years
and assessed their hand function. We discovered that the expression
of key proteases (e.g. all four collagenases mentioned) correlated
with poor progression post-fasciectomy [26]. This reinforces their
role as key mediators of the disease process.
Whilst there is no animalmodel of Dupuytren's disease, a number of
in vitro models have been used to mimic aspects of the disease. These
include the ﬁbroblast-populated collagen lattice assay which measures
cell-mediated contraction [27]. Fibroblasts from Dupuytren's disease
patients have been shown to generate enhanced contraction compared
to controls in the ﬁxed, or attached-delayed release (ADR) format of the
FPCL assay e.g. [28]. Broad spectrum small molecule inhibitors ofmetalloproteases have been shown to inhibit contraction in this and
other similar models [29,30]. This blockade is difﬁcult to dovetail with
the reported side-effects of pan-MMP inhibitors in clinical trials;
however, this reﬂects our increasing understanding that MMPs can
mediate both positive and negative effects and the need is to identify
speciﬁc MMPs as therapeutic targets [31].
In this study we measured metalloprotease gene expression in the
FPCL model, in lattices populated with ﬁbroblasts derived from
Dupuytren's disease palmar fascia. We then used siRNA knockdown
of individual MMPs to probe function. We also measured collagen
breakdown across the assay to determine if inhibition of collagenolysis
was responsible for inhibition of cell-mediated contraction. We found
that, of the collagenolytic MMPs, only knockdown of either MMP14 or
MMP2 inhibited contraction, with no concomitant change in collagen
breakdown. This, and our earlier research in man, establishes these
enzymes as key players in Dupuytren's disease, highlighting them as
potential drug targets and/or biomarkers of disease progression.
2. Material and methods
2.1. Cell culture
Primary ﬁbroblasts were derived by explant outgrowth from the
nodular palmar fascia of Dupuytren's disease patients undergoing
fasciectomy (as previously described [32]) and used up to passage 5.
Cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM)
supplementedwith 10% (v/v) foetal calf serum (FCS), 100 IU/ml penicil-
lin and 100 μg/ml streptomycin at 37 °C, 5% CO2.
2.2. Fibroblast-populated collagen lattice (FPCL)
Collagen contractionwas assessed using a ﬁxed FPCL format (n=4).
Rat tail type 1 collagen (First Link, UK) was combined 9:1 with 10×
serum-free DMEM to give a ﬁnal concentration of 1.85 mg/ml collagen
and neutralized with 10 M NaOH. Collagen was then combined at a
ratio of 1:1 with cells suspended at 4×105 cells/ml in serum-free
DMEM. Final concentration of collagen and cells were 0.925 mg/ml
and 2×105 cells/ml respectively. The collagen/cell suspension was
added 0.5 ml/well in a 24-well plate and allowed to form a gel at
37 °C for 1 h. Serum-freemedium(0.5 ml/well)was added and collagen
lattices, attached to thewells, were allowed to develop tension over 24,
48 and 72 h prior to their release or harvest. One hour before the release
of gel (using a pipette tip to detach the gel from the plastic of the
well), the serum-free medium was replaced with complete medium
containing 10% FCS. All conditioned media were harvested and stored
at−80 °C for downstream analysis.
Collagen lattices were harvested directly in Trizol reagent (Invi-
trogen) after 24, 48 and 72 h of tension and also at 3 h and 24 h
post release. Contraction was monitored using a ﬂatbed scanner (HP
Scanjet 3800) on transient removal of plates from the incubator and
quantiﬁed using the image processing software Image J (http://
rsbweb.nih.gov/ij/). Images were taken at release and across the sub-
sequent 24 h.
2.3. RNA extraction and synthesis of complementary DNA
Gels (and the equivalent cells from monolayer culture) were
harvested directly into Trizol (Invitrogen, UK). After complete suspen-
sion, chloroform was added (200 μl/ml Trizol), vortexed and centri-
fuged at 12,000 g for 15 min at 4 °C. The clear aqueous layer was
placed into a separate tube and a total of 0.5× volume of 100% ethanol
was added and mixed. Samples were then applied onto spin columns
(RNeasy Mini Kit, Qiagen, UK) and RNA puriﬁcation performed accord-
ing to the manufacturer's instructions. RNA samples were quantiﬁed
using a NanoDrop spectrophotometer (NanoDrop technologies,
Wilmington, DE) and stored at −80 °C. RNA (250 ng) was converted
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volume of 20 μl according to themanufacturer's instructions and stored
at−20 °C.
2.4. Quantitative real time-PCR
Quantitation of single gene expression was carried out on the ABI
Prism 7500 or 7900 sequence detection system (Applied Biosystems)
following the manufacturer's protocol. The sample (5 ng cDNA or
1 ng for 18S rRNA analyses) was added to the PCR reaction mixture
containing 50% 2× mastermix, 100 nmol/l of forward and reverse
primer, 200 nmol/l probe in a ﬁnal volume of 25 μl. The PCR protocol
involved 2 min at 50 °C, 10 min at 95 °C, then 40 cycles each consist-
ing of 15 s at 95 °C and 1 min at 60 °C. The expression of MMPs,
ADAMTSs and TIMPs, 18S rRNA and β-actin housekeeping genes
was measured using a custom Taqman® Low Density Array (TLDA)
(Applied Biosystems) on the ABI Prism 7900 system. For the ampliﬁ-
cation reactions 100 ng/μl of cDNA was combined with master mix to
a ﬁnal volume of 100 μl and applied to each port of the TLDA. In order
to compare expression of all genes, expression was normalised to
either β-actin or 18S rRNA using a transformation proportional to
normalised copy number (2−ΔCT), where ΔCT is CT of the gene of
interest — CT of housekeeping gene (CT = threshold cycle).
2.5. Hydroxyproline assay
Hydroxyproline (OH-Pro) was measured in conditioned medium
using a microtitre modiﬁcation of the method described by Bergman
and Loxley (1963) [33] to quantify collagen release.
2.6. RNA interference (siRNA)
Efﬁcacy of knockdown for all siRNAs was initially assayed in cells
in monolayer culture using qRT-PCR to measure expression of the
target gene. In order to knock down gene expression in the FPCL
assay, two rounds of siRNA transfection were used. Cells were plated
in a 6 well plate (2×105 cells/well) and at ~80–90% conﬂuency, trans-
fected (using DharmaFECT1 4 μl/well) with 5 nM siRNA (Qiagen)
individually targeting MMP1, MMP2, MMP3, MMP13 or MMP14 or a
non-targetting siRNA control (AllStars, Qiagen). A mock transfection
containing no siRNA and a negative control with no manipulation ofFig. 1. Fixed ﬁbroblast-populated collagen lattice model. Fibroblasts derived from the nodul
Material and methods). Contraction is shown as percentage of the lattice compared to t=0.
bars are s.e.m.the cells were also included. Cells were incubated for 48 h before a
second round of transfection of the same siRNAs for 24 h. Cells were
then trypsinised and seeded into the FPCL assay as before.
2.7. Gelatin zymography
Samples were electrophoresed under nonreducing conditions by
SDS–PAGE in 10% polyacrylamide gels copolymerised with 1% gelatin.
Gels were washed vigorously twice for 15 min in 2.5% Triton X-100 to
remove SDS, then incubated overnight in 50 mM Tris/HCl, pH7.5,
5 mM CaCl2 at 37 °C. Gels were then stained with Coomassie Brilliant
Blue and quantiﬁed using the Odyssey imaging system (Li-COR, USA).
Parallel gels were incubated in buffers containing 5 mM EDTA to
show that lysis of gelatin was due to metalloprotease activity.
2.8. Statistical analysis
Data are presented as mean value+/−SEM. Statistical analysis uti-
lised either pairwise comparison by two-tailed Student's t-test or for
groups of three of more, ANOVA with Tukey's post test in either Micro-
soft Excel or GraphPad Prism 4 (GraphPad Software, La Jolla, CA).
3. Results
3.1. Fibroblast-populated collagen lattice model
Initiallywe veriﬁed thatﬁbroblasts derived from the palmar fascia of
Dupuytren's disease patients would reproducibly contract a collagen
lattice. Fig. 1 shows contraction in the ﬁxed FPCL format using cells
derived from four independent patients. The kinetics of contraction
was similar across the patient cell lines with initial rapid contraction
upon release of the lattice, followed by a slower phase to 24 h. This is
in broad agreement with published data for this assay [28,29,34].
Expression of α-smooth muscle actin was detected in tissue, cells in
monolayer culture and in the FPCL by immunochemistry (data not
shown).
3.2. Protease gene expression
In order to ascertain if the pattern of metalloprotease gene expres-
sion in the isolated cells was similar to that seen in the tissue, thees of four independent Dupuytren's disease patients were used in the FPCL model (see
The insert shows the ﬁrst 3 h of the time course on different scale axes for clarity. Error
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independent Dupuytren's disease patients and cultured in monolayer.
Fig. 2 shows e.g. high expression ofMMP2,MMP14, ADAMTS1, ADAMTS2,
TIMP1, TIMP2, TIMP3 with lower expression of MMP1, MMP3 and
MMP13 in a similar pattern to that seen in our previous tissue study
[25].
Cells were then seeded into the FPCL assay and allowed to develop
tension for 24, 48 and 72 h prior to RNA isolation. Lattices were re-
leased at 48 h and RNA was also isolated at 3 h or 24 h after release.
The expression of MMP1, MMP2, MMP3, MMP13, MMP14 and TIMP1,
as genes encoding proteins involved in collagen turnover, were then
measured by qRT-PCR. Fig. 3 shows that for all genes measured,
expression was higher in the three-dimensional collagen lattice at
24 h, compared with monolayer culture. The expression of MMP1,Fig. 2.Metalloprotease gene expression in Dupuytren's disease ﬁbroblasts. Fibroblasts were
ﬁlled bars) and expanded in monolayer culture to passage 5. A., MMP, B., ADAMTS and C., TI
β-actin housekeeping gene.MMP3, MMP14 and TIMP1 then decreased as tension was allowed to
develop over 72 h, whereas the expression of MMP2 was unchanged
and that of MMP13 increased. Upon release, the expression of all
genes except MMP2 increased, with MMP14 and TIMP1 just below
signiﬁcance. All of these apart from MMP1 increased in expression
between the 3-h release and the 24-h release time point giving a
greater difference between tension compared to tension and release
at the 24-h compared to the 3-h release time point.
3.3. The function of speciﬁc metalloproteases in cell-mediated contraction
For eachofMMP1,MMP2,MMP3,MMP13 andMMP14, four individual
siRNAs per gene were tested for their ability to knock down expression
of the target gene, but not the other fourMMPs. A concentration range ofisolated from the nodules of two independent Dupuytren's disease patients (empty and
MP expression was analysed using Taqman® Low Density Array and normalised to the
Fig. 3. Metalloprotease and inhibitor gene expression during the FPCL model. Dupuytren's disease ﬁbroblasts were expanded in monolayer culture (M) and seeded into the FPCL
model. Lattices were harvested directly into Trizol at 24, 48 and 72 h and also at 3 or 24 h after release (following 48 h of tension). Gene expression (A., MMP-1; B., MMP-13; C.,
MMP-2; D., MMP-14; E., MMP-3; F., TIMP-1) was measured using Taqman® Low Density Array and normalised to the β-actin housekeeping gene. Data are shown as mean+/−s.e.m.,
n=3 and compared using ANOVA with Tukey's post test for samples across tension, or t-test for pairwise comparison of tension vs. release: *, pb0.05; **, pb0.01.
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72 h (data not shown). Two siRNAs were then selected for trial in the
FPCL assay, where two rounds of transfection with the siRNA allowed
robust knock-down at 5 nM concentration. Fig. 4A and B shows knock-
down ofMMP2 andMMP14 in bothmonolayer culture (72 hwith trans-
fection of siRNA at t=0 and 48 h) and after a further 48 h in the FPCL
assay using this format (see Material and methods).
Examining the combined data from cells isolated from three inde-
pendent Dupuytren's patients in the FPCL assay, transfection of the
non-targeting siRNA did not alter the amount or kinetics of contraction
compared to the mock transfection (data not shown). Fig. 5A shows
that knockdown of MMP3 or MMP13 did not alter contraction, whilst
knockdown of MMP1 increases contraction signiﬁcantly in the ﬁrst
30 min after release, though this then equalises at 1 h and beyond.
Knockdown ofMMP2 and particularlyMMP14 slows contraction across
the time course, with overall contraction at 24 h remaining signiﬁcantly
diminished (Fig. 5B and C).3.4. Gelatin zymography
Since MMP-14 can activate proMMP-2, the activity of MMP-2 was
measured in the conditioned medium from the FPCL assay by gelatin
zymography. Fig. 4C shows that knockdown of MMP2 decreases
activity due to proMMP-2 though there remains some active MMP-2
whilst knockdown of MMP-14 has no effect on proMMP-2, but
completely abrogates active MMP-2 (note that residual proMMP-2
activity comes from the FCS in the culture medium as shown).
3.5. Collagen turnover
Initial data demonstrate that the concentration of hydroxyproline
in the conditioned medium increases across 72 h of tension in the
FPCL format but is further increased upon lattice release and contrac-
tion and this is replicated in the later knockdown experiments
(Fig. 6A and B). Speciﬁc knockdown of MMP1, MMP2, MMP3,
Fig. 4. Knockdown of MMP gene expression using siRNA. Dupuytren's disease ﬁbroblasts were expanded in monolayer culture and either untreated (Con), mock transfected (Mock)
or transfected with 5 nM siRNA, non-targetting (Scr) or targeting MMP-2 or MMP-14. Cells were re-transfected at 48 h, incubated for a further 24 h and seeded into the FPCL model.
Gene expression (A., MMP-14 and B., MMP-2) was monitored by qRT-PCR prior to seeding into the FPCL (monolayer) and at the end of the contraction phase (FPCL). Data are n=1
for monolayer and mean+/−s.e.m., n=3 for FPCL and compared using t-test: *, pb0.05; **. C. Conditioned medium from the end of the contraction phase was subjected to gelatin
zymography.
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by this measure, either during tension or release phase of the FPCL
assay (Fig. 6B).
4. Discussion
The molecular mechanisms underlying Dupuytren's disease are
complex. The accumulation of a collagen-rich extracellular matrix
suggests decreased proteolytic activity, whereas the irreversible con-
traction of the cords suggests matrix remodelling must still occur.
Since several broad spectrum MMP inhibitors, trialled in cancer, dis-
played a musculoskeletal toxicity which included a Dupuytren's-like
contracture, it is important to understand the function of speciﬁc
MMPs in the pathophysiology of the disease. There are no animal
models of Dupuytren's disease therefore we sought to do this in vitro.
Cells were isolated from the nodules of Dupuytren's disease
palmar fascia by explant outgrowth onto tissue culture plastic. The
expression of the entire MMP, ADAMTS and TIMP families was mea-
sured in cells cultured from two independent patients using a quanti-
tative Taqman® low density array method. A broad correlation in the
relative levels of many of these genes (e.g. MMP1, MMP2, MMP3,
MMP13, MMP14, ADAMTS1, ADAMTS2, TIMP1, TIMP2, TIMP3) was
observed between the cells in culture and that measured directly in
patient tissue in our earlier study [25]. Since the cells were at passageﬁve in culture, this may suggest a stable genetic or epigenetic compo-
nent to their regulation, either directly on individual genes, or more
likely via an autocrine mechanism of cell signalling (e.g. Wnt or
TGFβ [5,35]). Measurement of steady state mRNA as a surrogate for
protein or activity levels ignores the potential for these post-
transcriptional or post-translational levels of regulation, but allows
for a greater range of proteases and inhibitors to be measured and
increased sensitivity.
Several studies have compared the contractile properties of
Dupuytren's cord- or nodule-derived ﬁbroblasts with control cultures
in the ﬁbroblast-populated collagen lattice model [28,36–38]. Results
varied depending on the model of contraction used, but the consen-
sus appears to be that Dupuytren's ﬁbroblasts can generate signiﬁ-
cantly increased contractile force compared with control cells, with
nodule-derived cells showing greatest contraction. We therefore
chose to dissect MMP function in the ﬁxed FPCL. In such models,
broad-spectrum synthetic MMP inhibitors have been shown to inhibit
contraction [29,39,40]. This blockade of contraction is difﬁcult to
dovetail with the reported side effects of some of these MMP inhibi-
tors in clinical trials; however, this may reﬂect the fact that culture
models of collagen lattice contraction only represent a single facet
of a more complex disease process. Ilomastat, an inhibitor with nano-
molar Ki against many MMPs [41], only inhibits contraction by DD
ﬁbroblasts in the FPCL at 100 μM [29], though this may reﬂect the
Fig. 5. The impact of speciﬁcMMPknockdownof collagen gel contraction. Dupuytren's disease ﬁbroblasts transfectedwith 5 nMsiRNA targeting speciﬁcMMPswere seeded into the FPCL
model (see Material and methods). A. Non-targetting siRNA (scrambled), compared to siRNA targeting MMP-1, MMP-3 or MMP-13. B. Non-targetting siRNA (scrambled) compared to
siRNA targeting MMP-2 or MMP-14. Data shown are mean of three experiments (n=3 each, therefore n=9) +/−s.e.m. using independent Dupuytren's disease patients. The insert
shows the ﬁrst hour of the time course on different scale axes for clarity. Targeting siRNA is compared to scrambled using t-test: *, pb0.05; **, pb0.01; ***, pb0.001. C., An example of
collagen lattices (as before) at the end of the contraction phase.
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Fig. 6. Collagen degradation in the FPCL model. Hydroxyproline release into the condi-
tioned medium was assayed as a measure of collagen breakdown. A., at 24, 48 and 72 h
of tension and also at 3 or 24 h after release (following 48 h of tension); B., at the end of
the tension (empty bars) and release (ﬁlled bars) phase of the FPCL model. Data are
shown as mean+/−s.e.m., n=3 and compared using ANOVA with Tukey's post test
for samples across tension, or t-test for pairwise comparison of tension vs. release:
*, pb0.05; **, pb0.01; ***, p,0.001.
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Ilomastat inhibits MMP activity in conditioned medium effectively at
25 μM (though this still provides no information about inhibition in
the collagen lattice itself), but, at this concentration, has no effect on
contraction (data not shown).
We probed function of individual proteases in cell-mediated con-
traction by using siRNA to knockdown MMPs involved in collagen
metabolism, i.e. MMP1, MMP2, MMP3 (as an activator of procolla-
genases), MMP13 and MMP14. Using a double transfection protocol,
we minimised the concentration of siRNA needed to achieve efﬁcient
knockdown, thus abrogating problems of toxicity that might confound
the contraction assay at higher concentrations. Knockdown of MMP3
or MMP13 had no impact on contraction, whereas knockdown of
MMP1 gave more rapid contraction in the period immediately post
release. The action of MMP-1 might therefore be to decrease tension
in the ﬁxed phase of the FPCL via reorganisation of the collagen lattice.
The inability ofMMP-8 orMMP-13, the other two classical collagenases,
to compensate, may reﬂect their comparatively low expression
compared to MMP-1 (see Fig. 2A). Knockdown of either MMP14 or
MMP2 led to a decreased contraction of the collagen lattice with slower
kinetics, particularly for MMP14. MMP-14 can activate proMMP-2 [42]
at the cell surface in a process also involving TIMP-2 and we show
that knockdown of MMP14 decreases the level of active MMP-2 in the
conditionedmediumof the contracted collagen latticeswithout altering
the level of proMMP-2. It is uncertain if the action of MMP-14, in
promoting contraction, is solely via proMMP-2 activation, since MMP-
14 is a collagenase in its own right. Both enzymes also have activities
outside of their matrix-degrading capabilities, e.g. MMP-14 mediates
the ectodomain shedding of the CD44 hyaluronan receptor [43] and of
syndecan 1 [44] with effects on cell migration and can also enhance
latent TGFβ activation [45]; MMP-2 can cleave MCP-3/CCL7 [46]
which itself displays cross-talk with TGFβ in ﬁbrosis [47]. Interestingly,
in tumour cells, constitutive overexpression of MMP-14, accompaniedby activation of endogenous proMMP-2 leads to enhanced contraction
of collagen gels [48]. MMP-14 is also insensitive to inhibition by TIMP-
1, the gene for which is highly expressed in DD tissue and in DD-
derived ﬁbroblasts [49].
Release of hydroxyproline, a marker for collagen breakdown, was
seen across the FPCL model (Fig. 6), however, no alteration in the
level of the marker was seen upon knockdown of each MMP. Interest-
ingly, Ilomastat, as a pan-MMP inhibitor, did abrogate hydroxyproline
release, despite having no signiﬁcant effect on contraction (data not
shown). If pericellular collagen turnover is the essential feature of
contraction, it is likely that this is simply overwhelmed by overall
collagenase activity in the bulk of the gel and is therefore obscured in
the conditioned medium. In a study utilising ﬁbroblasts derived from
MMP null mice deﬁcient in single collagenases, only MMP-14 was
essential for cell-associated collagen degradation [50]. In the presence
of plasminogen (providing a pathway for activation of proMMPs apart
from proMMP-14), soluble collagenase activity was shown to mediate
collagenolysis distal from the cell, but the absence of any single collage-
nase (MMP2,MMP8,MMP9,MMP13,MMP14 orMMP16) was unable to
abrogate this [50]. MMP-14 has also been shown to be essential for the
invasion of tumour cells into native (i.e. cross-linked) collagen gels [51]
and is a key player in cell migration [49], whilst MMP14 null mice
display a signiﬁcant musculoskeletal phenotype, with decreased colla-
gen turnover [52].
5. Conclusion
In conclusion, our data highlight the potential for MMP-14 and/or
MMP-2 to be therapeutic targets in Dupuytren's disease, whilst inhi-
bition of MMP-1 may potentiate cell-mediated contraction. Despite
the phenotype of the MMP-14 homozygous null mouse [52], the
heterozygotes do not display similar defects of collagen turnover. A
speciﬁc peptide inhibitor of MMP-14 has been used in short term can-
cer models in mice with no reported toxicity [53] and a function-
blocking anti-MMP-14 antibody was tested in rats for 28 days without
adverse clinical or histological events [54]. Potent inhibitors of MMP-2
and MMP-14 inhibitors have also been synthesised [55]. Particularly if
topical application of such agents were developed, we suggest that
these would be useful in slowing Dupuytren's disease progression or
preventing post-operative recurrence of contraction. Data from the
Dupuytren's disease-derived ﬁbroblasts described here and from
our previous tissue studies [25,26], also suggest that the level of circu-
lating MMP-2 or MMP-14, or their ratio with TIMP-1, may provide a
biomarker for disease progression or be predictive of post-operative
recurrence.
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